DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation

Jin Il Kim, Sehee Park, Sangmoo Lee, Ilseob Lee, Jun Heo, Min Woong Hwang, Joon Yong Bae, Donghwan Kim, Seok Il Jang, Mee Sook Park, Man-Seong Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Influenza viruses are seasonally recurring human pathogens. Vaccines and antiviral drugs are available for influenza. However, the viruses, which often change themselves via antigenic drift and shift, demand constant efforts to update vaccine antigens every year and develop new agents with broad-spectrum antiviral efficacy. An animal model is critical for such efforts. While most human influenza viruses are unable to kill BALB/c mice, some strains have been shown to kill DBA/2 mice without prior adaptation. Therefore, in this study, we explored the feasibility of employing DBA/2 mice as a model in the development of anti-influenza drugs. Unlike the BALB/c strain, DBA/2 mice were highly susceptible and could be killed with a relatively low titer (50% DBA/2 lethal dose = 102.83 plaque-forming units) of the A/Korea/01/2009 virus (2009 pandemic H1N1 virus). When treated with a neuraminidase inhibitor, oseltamivir phosphate, infected DBA/2 mice survived until 14 days post-infection. The reduced morbidity of the infected DBA/2 mice was also consistent with the oseltamivir treatment. Taking these data into consideration, we propose that the DBA/2 mouse is an excellent animal model to evaluate antiviral efficacy against influenza infection and can be further utilized for combination therapies or bioactivity models of existing and newly developed anti-influenza drugs.

Original languageEnglish
Pages (from-to)866-871
Number of pages6
JournalJournal of Microbiology
Volume51
Issue number6
DOIs
Publication statusPublished - 2013 Dec 1
Externally publishedYes

Fingerprint

Inbred DBA Mouse
Drug Evaluation
Human Influenza
Animal Models
Oseltamivir
Antiviral Agents
Orthomyxoviridae
Vaccines
Viruses
H1N1 Subtype Influenza A Virus
Neuraminidase
Feasibility Studies
Pandemics
Korea
Infection
Pharmaceutical Preparations
Phosphates
Morbidity
Antigens

Keywords

  • adaptation
  • animal model
  • antiviral
  • DBA/2 mouse
  • influenza virus

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology

Cite this

DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation. / Kim, Jin Il; Park, Sehee; Lee, Sangmoo; Lee, Ilseob; Heo, Jun; Hwang, Min Woong; Bae, Joon Yong; Kim, Donghwan; Jang, Seok Il; Park, Mee Sook; Park, Man-Seong.

In: Journal of Microbiology, Vol. 51, No. 6, 01.12.2013, p. 866-871.

Research output: Contribution to journalArticle

Kim, JI, Park, S, Lee, S, Lee, I, Heo, J, Hwang, MW, Bae, JY, Kim, D, Jang, SI, Park, MS & Park, M-S 2013, 'DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation', Journal of Microbiology, vol. 51, no. 6, pp. 866-871. https://doi.org/10.1007/s12275-013-3428-7
Kim, Jin Il ; Park, Sehee ; Lee, Sangmoo ; Lee, Ilseob ; Heo, Jun ; Hwang, Min Woong ; Bae, Joon Yong ; Kim, Donghwan ; Jang, Seok Il ; Park, Mee Sook ; Park, Man-Seong. / DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation. In: Journal of Microbiology. 2013 ; Vol. 51, No. 6. pp. 866-871.
@article{4752b58de31746668049bf6a42ab8b48,
title = "DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation",
abstract = "Influenza viruses are seasonally recurring human pathogens. Vaccines and antiviral drugs are available for influenza. However, the viruses, which often change themselves via antigenic drift and shift, demand constant efforts to update vaccine antigens every year and develop new agents with broad-spectrum antiviral efficacy. An animal model is critical for such efforts. While most human influenza viruses are unable to kill BALB/c mice, some strains have been shown to kill DBA/2 mice without prior adaptation. Therefore, in this study, we explored the feasibility of employing DBA/2 mice as a model in the development of anti-influenza drugs. Unlike the BALB/c strain, DBA/2 mice were highly susceptible and could be killed with a relatively low titer (50{\%} DBA/2 lethal dose = 102.83 plaque-forming units) of the A/Korea/01/2009 virus (2009 pandemic H1N1 virus). When treated with a neuraminidase inhibitor, oseltamivir phosphate, infected DBA/2 mice survived until 14 days post-infection. The reduced morbidity of the infected DBA/2 mice was also consistent with the oseltamivir treatment. Taking these data into consideration, we propose that the DBA/2 mouse is an excellent animal model to evaluate antiviral efficacy against influenza infection and can be further utilized for combination therapies or bioactivity models of existing and newly developed anti-influenza drugs.",
keywords = "adaptation, animal model, antiviral, DBA/2 mouse, influenza virus",
author = "Kim, {Jin Il} and Sehee Park and Sangmoo Lee and Ilseob Lee and Jun Heo and Hwang, {Min Woong} and Bae, {Joon Yong} and Donghwan Kim and Jang, {Seok Il} and Park, {Mee Sook} and Man-Seong Park",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s12275-013-3428-7",
language = "English",
volume = "51",
pages = "866--871",
journal = "Journal of Microbiology",
issn = "1225-8873",
publisher = "Microbiological Society of Korea",
number = "6",

}

TY - JOUR

T1 - DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation

AU - Kim, Jin Il

AU - Park, Sehee

AU - Lee, Sangmoo

AU - Lee, Ilseob

AU - Heo, Jun

AU - Hwang, Min Woong

AU - Bae, Joon Yong

AU - Kim, Donghwan

AU - Jang, Seok Il

AU - Park, Mee Sook

AU - Park, Man-Seong

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Influenza viruses are seasonally recurring human pathogens. Vaccines and antiviral drugs are available for influenza. However, the viruses, which often change themselves via antigenic drift and shift, demand constant efforts to update vaccine antigens every year and develop new agents with broad-spectrum antiviral efficacy. An animal model is critical for such efforts. While most human influenza viruses are unable to kill BALB/c mice, some strains have been shown to kill DBA/2 mice without prior adaptation. Therefore, in this study, we explored the feasibility of employing DBA/2 mice as a model in the development of anti-influenza drugs. Unlike the BALB/c strain, DBA/2 mice were highly susceptible and could be killed with a relatively low titer (50% DBA/2 lethal dose = 102.83 plaque-forming units) of the A/Korea/01/2009 virus (2009 pandemic H1N1 virus). When treated with a neuraminidase inhibitor, oseltamivir phosphate, infected DBA/2 mice survived until 14 days post-infection. The reduced morbidity of the infected DBA/2 mice was also consistent with the oseltamivir treatment. Taking these data into consideration, we propose that the DBA/2 mouse is an excellent animal model to evaluate antiviral efficacy against influenza infection and can be further utilized for combination therapies or bioactivity models of existing and newly developed anti-influenza drugs.

AB - Influenza viruses are seasonally recurring human pathogens. Vaccines and antiviral drugs are available for influenza. However, the viruses, which often change themselves via antigenic drift and shift, demand constant efforts to update vaccine antigens every year and develop new agents with broad-spectrum antiviral efficacy. An animal model is critical for such efforts. While most human influenza viruses are unable to kill BALB/c mice, some strains have been shown to kill DBA/2 mice without prior adaptation. Therefore, in this study, we explored the feasibility of employing DBA/2 mice as a model in the development of anti-influenza drugs. Unlike the BALB/c strain, DBA/2 mice were highly susceptible and could be killed with a relatively low titer (50% DBA/2 lethal dose = 102.83 plaque-forming units) of the A/Korea/01/2009 virus (2009 pandemic H1N1 virus). When treated with a neuraminidase inhibitor, oseltamivir phosphate, infected DBA/2 mice survived until 14 days post-infection. The reduced morbidity of the infected DBA/2 mice was also consistent with the oseltamivir treatment. Taking these data into consideration, we propose that the DBA/2 mouse is an excellent animal model to evaluate antiviral efficacy against influenza infection and can be further utilized for combination therapies or bioactivity models of existing and newly developed anti-influenza drugs.

KW - adaptation

KW - animal model

KW - antiviral

KW - DBA/2 mouse

KW - influenza virus

UR - http://www.scopus.com/inward/record.url?scp=84891612766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891612766&partnerID=8YFLogxK

U2 - 10.1007/s12275-013-3428-7

DO - 10.1007/s12275-013-3428-7

M3 - Article

C2 - 24385366

AN - SCOPUS:84891612766

VL - 51

SP - 866

EP - 871

JO - Journal of Microbiology

JF - Journal of Microbiology

SN - 1225-8873

IS - 6

ER -